Regulatory Milestones Shaping Extractable and Leachable Testing in Pharma The regulatory framework governing Extractable and Leachable Testing in Pharma has […]
Extractable and Leachable Testing in Pharma: Complete Guide for Drug Manufacturers Read More »
Introduction: Nitrosamine control in continuous manufacturing is one of the most pressing quality and regulatory challenges facing pharmaceutical manufacturers today.
Why Researchers and Developers Choose to Order Custom PLGA Grades Choosing to order custom PLGA grades enables formulation scientists to
How to Order Custom PLGA Grades: Inquiry Process, Specifications, and Lead Times Read More »
Evaluating and controlling the shelf life of PLGA, PLA, and PCL is essential for preserving the physicochemical stability, mechanical properties,
What Is the Shelf Life of PLGA, PLA, and PCL? Storage and Handling FAQs Answered Read More »
Introduction: Why Demonstrating Peptide Sameness Is Analytically Challenging Establishing “sameness” for a traditional small-molecule generic drug generally involves confirming chemical
Which Analytical Techniques Are Needed to Prove Peptide Sameness in an ANDA Submission? Read More »
Introduction: When evaluating a contract research organization (CRO) for your drug development program, one of the first practical questions you
How Many Samples Can a Bioanalytical CRO Realistically Process Per Day? Read More »
Core Foundations of the Shifting Regulatory Landscape The regulatory assessment of therapeutic biologics has evolved significantly from a framework centered
Strategic Frameworks for Bioanalytical Method Development for POC Therapeutics Establishing robust analytical assays for peptide-oligonucleotide conjugates requires highly specialized methodologies
Introduction: Biosimilar stability testing is not simply a regulatory checkbox — it is a rigorous scientific discipline that determines whether
Stability-Indicating Mass Spectrometry Methods for Biosimilars Read More »
Introduction: The generic pharmaceutical industry operates on razor-thin timelines and tighter regulatory scrutiny than ever before. For any manufacturer pursuing
Pre-ANDA Strategy: How to De-Risk Sameness Evaluation Early Read More »
